These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22580742)

  • 41. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Contribution of Microglia to Neuroinflammation in Parkinson's Disease.
    Badanjak K; Fixemer S; Smajić S; Skupin A; Grünewald A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroimaging of nonmotor features of Parkinson's disease.
    Deblieck C; Wu AD
    Rev Neurol Dis; 2008; 5(3):125-33. PubMed ID: 18838952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.
    Meredith GE; Totterdell S; Potashkin JA; Surmeier DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2(Suppl 2):S112-5. PubMed ID: 18585085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease.
    Postuma RB; Gagnon JF; Vendette M; Montplaisir JY
    Brain; 2009 Dec; 132(Pt 12):3298-307. PubMed ID: 19843648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The functional anatomy of noradrenergic neurons in Parkinson's disease.
    Soldani P; Fornai F
    Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
    [No Abstract]   [Full Text] [Related]  

  • 48. Multifactorial sleep disturbance in Parkinson's disease.
    Albers JA; Chand P; Anch AM
    Sleep Med; 2017 Jul; 35():41-48. PubMed ID: 28619181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?
    Hirsch EC; Hunot S; Damier P; Faucheux B
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S115-20. PubMed ID: 9749582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
    Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
    Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?
    Barzilai A; Melamed E; Shirvan A
    Cell Mol Neurobiol; 2001 Jun; 21(3):215-35. PubMed ID: 11569535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Parkinson's disease dementia: a neural networks perspective.
    Gratwicke J; Jahanshahi M; Foltynie T
    Brain; 2015 Jun; 138(Pt 6):1454-76. PubMed ID: 25888551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of T cells in the pathogenesis of Parkinson's disease.
    Chen Z; Chen S; Liu J
    Prog Neurobiol; 2018 Oct; 169():1-23. PubMed ID: 30114440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation.
    Lima MM; Reksidler AB; Vital MA
    J Neural Transm Suppl; 2009; (73):135-45. PubMed ID: 20411774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
    Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
    J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts.
    Politis M; Wu K; Loane C; Quinn NP; Brooks DJ; Oertel WH; Björklund A; Lindvall O; Piccini P
    Sci Transl Med; 2012 Apr; 4(128):128ra41. PubMed ID: 22491951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Variability in the clinical expression of Parkinson's disease.
    Wolters ECh
    J Neurol Sci; 2008 Mar; 266(1-2):197-203. PubMed ID: 17854836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.
    Chaudhuri KR; Schapira AH
    Lancet Neurol; 2009 May; 8(5):464-74. PubMed ID: 19375664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.